All News

EULAR flags

Improving Understanding in SSc

2026 EULAR Press Release

Systemic sclerosis is a rare connective tissue disorder characterised by autoimmune features with vascular manifestations, causing fibrosis of the skin and internal organs. EULAR is focused on systemic sclerosis as the rheumatic disease with the highest morbidity and mortality. New data presented at the EULAR 2026 Congress underscore key complications, and offer hope for a possible new therapeutic strategy.

Read Article
question mark

Immune Dimming or Immune Reset in RA: How Far Should We Go?

Aurelie Najm, MD, PhD

CD19-directed CAR T-cell therapy has rapidly moved into autoimmune disease, driven in large part by striking reports in SLE, where sustained drug-free remission has raised the possibility of a true immune reset. In RA, where multiple effective therapeutic classes already exist, the relevance of such deep immune interventions remains uncertain.

Read Article
Eular stage

New: Classification Critiera and Recommendations in SpA

2026 EULAR Press Release

ASAS and the SPARTAN have updated their key classification criteria for axial SpA (axSpA). EULAR has also recently revised their recommendations on the role of imaging in the diagnosis and clinical management of spondyloarthritis (SpA). Both were presented at the EULAR 2026 annual Congress in London.

Read Article
Baricitinib did not demonstrate non-inferiority w/ TNFi for first VTE in the RA-BRIDGE and RA-BRANCH trials. Identifying high-risk pts and individualizing tx is paramount. LB0009 @RheumNow #EULAR2026 https://t.co/MSiBq0FnEq

Links:

sheila RHEUMarampa ( View Tweet)
Abstr LB0009 Baricitinib vs TNFi in RA patients enriched for VTE risk. 3,640 patients. 3.7 years median follow-up. VTE: HR 1.61 (95% CI 0.97–2.66) non-inferiority not demonstrated MACE: HR 1.06 no cardiovascular excess Serious infections: HR 1.32 (p<0.05) @RheumNow https://t.co/NSNRJi9B4r

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Abstr LB0009 Baricitinib vs TNFi in VTE-enriched RA. 3,640 patients. 3.7 years. Safety endpoints VTE HR 1.61 non inferiority not met Serious infections HR 1.32 (p<0.05) MACE HR 1.06 reassuring @RheumNow #EULAR2026 https://t.co/nR6TMowlYS

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2026 Updated recommendations on the management of PMR &LVV. A pleasure to have been part of this huge piece of work, covering 3 distinct conditions, and both diagnosis & management principles. Watch this space for full guideline coming soon! #EULAR2026 @RheumNow https://t.co/CUvaQVSU8k

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2026 LB0006 Beyond conventional immunosuppressant, a multicentre RCT (N=145) in China showed mTOR-i Sirolimus + SOC met primary endpoint (SRI-4) vs PBO + SOC in #SLE. Favourable safety. Frequent AE: high cholesterol & low WCC. Unclear position in treatment pathway @RheumNow https://t.co/OiFp06467v

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
5 top abstracts in #Myositis @eular_org 1 #Nailfold #capillaries as an early marker of #IIM Rx 2 #brepocitinib +RCT #DM 3 & rapid skin improvement #CLASI 4 #Ab may help #IBM but neg primary endpoint 5 #criteria for #antisynthetase #EULAR2026 @RheumNow OP0168, 0166, 0164 POS264

Janet Pope Janetbirdope ( View Tweet)

Top 5 abst in #SjD #anifrolumab +RCT #ianalumab LTE Rx sustained #telitatacept +LTE #iana improves u/s parotids #TYK2 sig in#SjD OP0002, 0126, 127, 160 POS0284 #EULARbest #EULAR2026 @RheumNow @eular_org

Janet Pope Janetbirdope ( View Tweet)

#EULAR2026 LB0007 Phase 2 RCT of Nipocalimab, an FcRn-i in moderate-to-severe #SLE, with mandatory GC taper =<7.5mg/d by WK16: met primary endpoint at WK24 (SRI-4) vs PBO. Effect size better in Ab+, Ab-High & IFN-High. 23% had IgG<3 at WK58 but SIE. Phase 3 is underway @RheumNow https://t.co/EpgNOHcEqC

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Do you target #DORIS / remission in #SLE pts #EULAR2026 @RheumNow @eular_org

Janet Pope Janetbirdope ( View Tweet)

Aiming for #DORIS #SLE #remission Or #LLDAS in #SLE Related to ⬆️survival #deep outcome in RCTs ➡️archived in #deucravacitinib ph2 #LTE & ph3 #dapirolizumab & #obintuzimab -achieved in #CAR-T trials in #lupus POS0683, 1364, 0695, OP0338 & several 🚗 T abst #EULAR2026 @RheumNow

Janet Pope Janetbirdope ( View Tweet)

Do GLP-1 agonists achieve meaningful weight loss in patients with RMDs? RISE registry Retrospective N=60,206 Tirzepatide: lost 8% Semaglutide: list 6% At 12 months PsA had the highest usage OP0112 #EULAR2026 @RheumNow https://t.co/P3CTgiwqCr

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
BARI vs TNFi in VTE-enriched #RA pts (RA-BRIDGE + RA-BRANCH, n=3,640, ~3.7 yrs follow-up): VTE non-inferiority not met (HR 1.61, CI 0.97–2.66). But absolute rates low (2.5% vs 1.7%) and MACE was similar (HR 1.06). Serious infections ↑ with BARI. @RheumNow #EULAR2026 LB0009

Jiha Lee JihaRheum ( View Tweet)

What drives progression to difficult-to-treat RA? 20-year cohort 675pts -18.8% developed D2T RA -Younger age, higher HAQ & prior steroid exposure asso w/ D2T RA -Earlier b/tsDMARD initiation protective -No diff TNFi vs non-TNFi first-line strategy Disease severity and https://t.co/SJDv9HCbLv

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
JAK-SPARE: Ph3 RCT on baricitinib for rem induxn in early PMR. BARI was effective vs. PBO in inducing & maintaining GC free rem. No new safety signals. New tx option for PMR (esp early). Decreases GC dependence & side effects. LB0005 @RheumNow #EULAR2026 https://t.co/mWrr1RdPCm

Links:

sheila RHEUMarampa ( View Tweet)
#antisynthetase #EULAR/ACR #classification #criteria #EULAR2026 @RheumNow Based on >2k pts Probable v definite Ignore low + #synthetase #antibodies Seems reasonable and applicable ➡️my opinion https://t.co/MyCRiCSiGo

Links:

Janet Pope Janetbirdope ( View Tweet)
LB0002: Sonelokimab (IL-17A/F Nanobody, ~40 kDa) in #axSpA Phase 2: 81% ASAS40 and 54% ASAS partial remission at 12 weeks. Mean ASDAS improvement of −2.0 from baseline. @RheumNow #EULAR2026 https://t.co/TjvtnFPCdj

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2026 Recommendations: Immunization (new since 2011) - Vaccinate early regardless of dz acitiviry - HBV booster/passive if poor response - Yellow fever may be considered on individual basis - Avoid live vaccines (mostly) in newborn exposed in utero to biologic @RheumNow

Jiha Lee JihaRheum ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×